Prof. Dr. med. Dr. h.c.
Former professor and director of the Clinic for Radiotherapy and Radiation Oncology
TUM School of Medicine, TUM university hospital "Klinikum rechts der Isar"
Direktor of the TUM Institute for Advanced Study
born December 15, 1944
Scientific and Clincal Work | Education
Michael Molls was the chairholder and the director of the clinic for radiotherapy and radiation oncology at TUM from 1992 to 2014. Further activities included serving as member of the Board of Management and the Supervisory Board at the TUM hospital “Rechts der Isar” and head of the Tumour Centre (Tumorzentrum) München of both Ludwig Maximilian University (LMU) and TUM. He was particularly committed to process, result and structure quality of interdisciplinary oncology.
As president of the German Society for Radiation Oncology (DEGRO) and head of the DEGRO Academy, Michael Molls contributed to the introduction of interdisciplinary guidelines for the treatment of cancer patients (in cooperation with the German Cancer Society) and he developed a curriculum for specialization in radiation oncology based on European recommendations. He promoted the integration of radiobiological and physical-medical research in radiation oncology.
In 1976, Michael Molls succeeded in cultivating mouse preimplantation embryos in vitro. New developmental and radiobiological (X-rays, neutrons, tritium, combination of radiation with pollutants, chemotherapeutic substances, hyperthermia) insights were gained using this system of fast proliferating stem cells.
From 2010 to 2016, Michael Molls was the co-speaker of the cluster of excellence “Munich Centre for Advanced Photonics” (MAP) of the German Research Founda-tion (Deutsche Forschungsgemeinschaft) and responsible for the biomedical area of this research network. Together with colleagues he performed experiments with laser generated protons/ions and investigated biological effects of nanosecond proton irradiation (cell death, chromosomal aberrations, DNA repair). MAP has built the framework for the “Center for Advanced Laser Applications” (CALA) at LMU and TUM. F. Krausz/LMU and M. Molls/TUM initiated the CALA project (63 Mio EUR). In 2011 it was recommended for funding by the German Science Council (Wissenschaftsrat).
Michael Molls focussed his clinical research in cancer patients on tumour hypoxia, tumour blood perfusion, innovative imaging techniques for therapy planning, high-precision and individualized radiotherapy and the initiation of multicenter studies funded by the DFG and the German Federal Ministry for Education and Research (BMBF).
Renowned is the work of the Molls group on radiosurgery and stereotactic radiation treatment of brain tumours, early lung carcinomas and liver metastases as well as on post-radiotherapy quality of life in breast- and prostate cancer.
As speaker of the TUM Senior Excellence Faculty and with colleagues of the group of the “TUM Emeriti of Excellence” Michael Molls founded in 2016 the “TUM Sustainability Forum”. The Forum organizes symposia (Sustainable Risk Management, Sustainable Development in Africa, Violated Earth – Violent Earth, Discovery of X-Rays – a Big Bang for Science, Circular Economy, etc.). Since 2020 Michael Molls is the Director of the TUM Institute for Advanced Study.
Michael Molls is the author of approximately 400 reviewed publications and editor of textbooks, monographs and series of books on radiation oncology, radiation biology, medical physics and recently on the topic of sustainability.
He supervised 14 habilitations (professorial teaching qualification processes). Seven of his staff have been appointed to professorships or executive positions in Germany and abroad.
Study of medicine and licensing examination, University of Freiburg
Occupational medicine in Turkey (Istanbul) and former Yugoslavia
Assistant at the Institute of Pharmacology, doctorate, experimental study on “Anaphylactic Shock and Treatment in Guinea Pigs”, University of Freiburg
Assistant and consultant at the Institute for Radiation Biology and at the Radiation Clinic of the Essen University Clinic. Habilitation and Venia legendi (university instruction licence) for embryology, radiation biology and radiation therapy
Professor and director of the Radiation Therapy and Radiation Oncology Clinic at the “Klinikum rechts der Isar” (TUM university hospital)
Speaker of the “TUM Senior Excellence Faculty” (group of the “TUM Emeriti of Excellence”) and member of the “TUM Extended Board of Management”
Director of the “TUM Institute for Advanced Study” (IAS)
- Member of expert commissions of the German Council of Science and Humanities, DFG, Helmholtz Association of German Research Centres, federal and state ministries, and of national and international advisory boards, chairman of review committees
- Reviewer for national and international journals
- Member of the academic directorate of the TUM research reactor (1996-2003)
- President of the German Society for Radiation Oncology (DEGRO) (1997-1999)
- Head of the Tumor Center Munich (TZM) of LMU and TUM (2001-2003)
- President of the academy for advanced training and continuing education of the DEGRO (2004-2009)
- Member of the board of management (from 2006), co-spokesperson (2010-2016) and head of biomedicine for the cluster of excellence “Munich Centre for Advanced Photonics” (MAP) of the German Research Foundation (DFG)
- Member of the review boards “cancer research” and “medical technology” of the DFG (2007-2012)
- Member of the Peer Review College of the Danish Council for Strategic Research (2008)
- Coordinator of the European radiation biology project CARDIORISK (EU 7th framework programme) (2008-2011)
- Member of the academic advisory board for the ELI Beamlines Facility, Prague (Extreme Light Infrastructure, European Project) (2010-2015)
- Member of the board of directors of the Centre for Advanced Laser Applications (CALA) (2012-2016)
- Member of the Scientific Advisory Board of the National Center for Tumor Diseases Heidelberg, Dresden (NCT) (since 2015)
- Spokesperson for the TUM Senior Excellence Faculty (Emeriti of Excellence) and member of the Extended Board of TUM (since 2015)
- Member of the Scientific Advisory Board of the Munich Center for Technology in Society (MCTS) of TUM (since 2019)
- Director of the TUM Institute for Advanced Study (since 2020)
- Hanns Langendorff Prize (1979)
- Member of the German National Academy of Sciences “Leopoldina” (since 1998)
- President of the joint annual congress of the German and Austrian Societies of Radiation Oncology and the German Society for Medical Physics (DGMP) (2000)
- Honorary member of the Austrian and the German Societies of Radiation Oncology (2004, 2014)
- Honorary award of the Munich Tumour Centre (2007)
- Chairman of the “Alfred Breit Award” committee (since 2013)
- Paul Harris Fellow, Rotary (2017)
- Dr. h. c. Cyprus University of Technology (2019)
You can download "Explanations of honors and awards" here [PDF 215 KB]
Vaidya JS, et al.: “Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial”. Lancet. 2010; 376: 91-102. (Publikation unter Beteiligung der Gruppe Molls)
Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, Molls M: “Stereotactic hypofractionated radiotherapy in early stage I (T1-2 N0 M0) non-small cell lung cancer (NSCLC)”. Acta Oncol. 2006; 45: 796-801.
Geinitz H, Zimmermann FB, Thamm R, Schumertl A, Busch R, Molls M: “3D conformal radiation therapy for prostate cancer in elderly patients”. Radiother Oncol. 2005; 76: 27-34.
Cornforth MN, Greulich-Bode KM, Loucas BD, Arsuaga J, Vasquez M, Sachs RK, Brückner M, Molls M, Hahnfeldt P, Hlatky LR, Brenner DJ: “Chromosomes are predominantly located randomly with respect to each other in interphase human cells”. J Cell Biol. 2002; 159: 237-244.
Molls M, Streffer C, van Beuningen D, Zamboglou N: “X-irradiation in G2-phase of 2-cell mouse embryos in vitro: cleavage, blastulation, cell kinetics and fetal development”. Radiation Research. 1982; 91: 219-234.